#India #Clinical Trials #Amsterdam #myTomorrows #Asia-Pacific

myTomorrows Expands Operations into Asia-Pacific

In a significant move towards enhancing healthcare access, myTomorrows has declared its expansion into the Asia-Pacific (APAC) region, establishing a new operations hub in India. This strategic decision aims to address the ongoing challenges surrounding access to clinical trials and expanded access programs in a diverse and rapidly growing market.

With its innovative platform, myTomorrows connects patients with a variety of treatment options. In just a few years, they have successfully guided over 11,000 patients and 2,000 physicians through the complexities of locating and accessing pre-approval treatments in over 40 countries. By leveraging advanced technologies, myTomorrows simplifies the process of discovering relevant clinical trials through AI-powered searches of public registries.

The Growing Need for Clinical Trial Access

The APAC region has witnessed a remarkable increase in clinical trial sites, surpassing that of the US and Europe in terms of year-on-year growth. Despite this increase, there are still substantial gaps preventing underserved populations from accessing these crucial trials. myTomorrows aims to close these gaps by providing tailored support for patient recruitment, expanded access programs (EAPs), and utilizing Real-World Data (RWD) to enhance BioPharma companies' efficiency in servicing patients across the APAC market.

One of the key challenges in the APAC region is the diversity of regulatory frameworks that vary significantly from one country to another. While countries like Australia and Japan maintain stringent regulations, others are adopting newer, more flexible systems. This variation can complicate the approval processes and access to investigational treatments. However, with its wealth of experience, myTomorrows is poised to effectively navigate these regulatory complexities, providing valuable insights to both patients and physicians alike.

Establishing Local Support Systems

From its base in India, myTomorrows plans to build a dedicated team of Patient Navigators. These specialists, trained with comprehensive medical knowledge, will provide personalized support in patients' native languages, alleviating the confusion surrounding clinical trials. Their mission will be to guide families as they search for investigational treatments and help demystify the clinical trial process.

Additionally, future plans include establishing a team of local site managers who will oversee physician support and manage regulatory affairs and supply chain logistics at the country level. The goal is to cultivate a robust operational foundation to effectively meet the growing needs of the APAC market.

Industry Collaboration and Conference Announcements

With this expansion comes the organization of the inaugural Pre-Approval Access to Medicines in Asia-Pacific Conference, scheduled to take place in Singapore on February 18-19, 2025. This event will assemble prominent figures from the BioPharma sector, regulatory agencies, and advocacy groups to tackle the intricate challenges of pre-approval access for medicines in this vital region.

As stated by Dr. Michel van Harten, CEO of myTomorrows, "This expansion is a crucial milestone in our commitment to ensuring that patients worldwide are fully informed about their treatment options." He expressed excitement about the potential impact the APAC team will have, particularly in a region that is undergoing significant transformation in clinical trial accessibility.

Conclusion

The expansion of myTomorrows into the APAC region marks a pivotal step in enhancing patient access to clinical trials and innovative treatments. By harnessing cutting-edge technology and focusing on personalized support, myTomorrows is set to play a transformative role in the clinical trial landscape of Asia-Pacific, ultimately benefiting countless patients and healthcare providers. As they continue to expand their operations, patients can look forward to improved access to potentially life-saving treatments and a more efficient healthcare system.